Cardiac amyloidosis
Cardiac amyloidosis happens when an abnormal protein called amyloid builds up in the heart muscle and forms deposits. The deposits can leave the heart stiff and unable to work the way it should, and people may have an abnormal heartbeat or an enlarged heart. It is one cause of cardiomyopathy. Amyloid can build up in other organs too, such as the kidney. In the United States the label of the medicine tafamidis gives cardiomyopathy caused by one type of amyloid in adults as its indication.
- Condition
- In this atlas
Overview
Technical summary
MeSH has no descriptor for cardiac amyloidosis. The wider descriptor Amyloidosis (D000686) is recorded here as a broad match; its scope note describes diseases linked by abnormal protein folding and deposition of amyloid. The MedlinePlus Genetics page describes a cardiac form of transthyretin amyloidosis, and the US tafamidis label names the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). Other types of amyloidosis can also involve the heart; this page does not separate the types.
Classification codes
-
D000686
Burden
No burden claims are published.
Claims and evidence
Context People with amyloidosis that affects the heart, as described in MeSH and MedlinePlus reference pages
- Recipient
- Recipient not specified
- Population
- People with amyloidosis, with emphasis on involvement of the heart. The pages are written for the public or as a vocabulary and give no study population, age range or risk group. The MedlinePlus Genetics page describes the transthyretin type.
- Care setting
- General health information for the public; no care setting is stated
- Geography
- United States (pages of US government agencies); the MeSH vocabulary is international
- Life stage
- Not stated in the pages for the heart form
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (descriptive statement)
Eligibility: inclusion criteria not stated; exclusion criteria not stated
- Included
- None stated
- Excluded
- None stated
The MeSH scope note for amyloidosis describes a group of diseases linked by abnormal protein folding and deposition of amyloid, with the deposits displacing normal tissue and disrupting its function. MedlinePlus says abnormal proteins called amyloids build up and form deposits, that the deposits can collect in organs such as the kidney and heart, and that this can leave an organ stiff and unable to work as it should. MedlinePlus Genetics says the cardiac form of transthyretin amyloidosis affects the heart and that people with cardiac amyloidosis may have an abnormal heartbeat and an enlarged heart.
Applies to Recipient not specified People with amyloidosis that affects the heart, as described in MeSH and MedlinePlus reference pages
- Certainty method
- Not assessed
- Limitations
- Vocabulary and patient-education pages from US government sources. MeSH has no descriptor for cardiac amyloidosis, so the scope note describes amyloidosis as a whole. The MedlinePlus Genetics page describes the transthyretin type only, and its list of cardiac findings is quoted only in part because the page's wording of the last finding looks like a source error. The pages give no study, no size of risk and no population beyond the general public.
- Last checked
- 2026-10-30
- Next evidence check due
- Not scheduled
Sources and citations (6)
-
Supports MeSH scope note for descriptor D000686 (Amyloidosis)
- Locator
- scopeNote.@value
- How it applies
- MeSH scope note of the descriptor Amyloidosis, which is wider than the heart form.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
54d0563e45b3bf8fa1c1bee0c833fb7035d74e96a0978f111ad84c17bac6d595- Reuse basis
- The NLM web policies page (sha256 c8b7026b5c3fcfd1b0cb88755077f6a99a5f2159eecd42b0e7d1a5ad9b30ec55) says works produced by the U.S. government are not subject to copyright protection in the United States and asks users to acknowledge NLM as the source. This copy was fetched on 2026-10-30 and may not reflect the most current data. The raw bytes are committed in the atlas repository.
-
Supports Amyloidosis (MedlinePlus health topic)
- Locator
- Summary, para 1, sentence 1
- How it applies
- What amyloidosis is.
- Retrieved
- Source effective date
- 2026-07-05
- Source state
- Current
- Version fingerprint
180c57d16d5511de7fadf3cc7fe19969b5d0139c61948bd94bd9bdbea5fd3604- Reuse basis
- MedlinePlus states that works produced by the federal government are not copyrighted, and lists the summaries on health topic pages and Genetics pages as public domain (the page titled Linking to and Using Content from MedlinePlus, fetched 2026-10-30, sha256 e0fbefd889f779a2537ed84f7649157343e52043a577e2a21ddaf9c416844161). It names the A.D.A.M. encyclopedia, drug monographs and many images as copyrighted; this atlas uses only the page summary text. The raw page is committed in the atlas repository. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only.
-
Supports Amyloidosis (MedlinePlus health topic)
- Locator
- Summary, para 1, sentence 2
- How it applies
- Organs where the deposits collect.
- Retrieved
- Source effective date
- 2026-07-05
- Source state
- Current
- Version fingerprint
180c57d16d5511de7fadf3cc7fe19969b5d0139c61948bd94bd9bdbea5fd3604- Reuse basis
- MedlinePlus states that works produced by the federal government are not copyrighted, and lists the summaries on health topic pages and Genetics pages as public domain (the page titled Linking to and Using Content from MedlinePlus, fetched 2026-10-30, sha256 e0fbefd889f779a2537ed84f7649157343e52043a577e2a21ddaf9c416844161). It names the A.D.A.M. encyclopedia, drug monographs and many images as copyrighted; this atlas uses only the page summary text. The raw page is committed in the atlas repository. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only.
-
Supports Amyloidosis (MedlinePlus health topic)
- Locator
- Summary, para 1, sentence 3
- How it applies
- Effect on the organs.
- Retrieved
- Source effective date
- 2026-07-05
- Source state
- Current
- Version fingerprint
180c57d16d5511de7fadf3cc7fe19969b5d0139c61948bd94bd9bdbea5fd3604- Reuse basis
- MedlinePlus states that works produced by the federal government are not copyrighted, and lists the summaries on health topic pages and Genetics pages as public domain (the page titled Linking to and Using Content from MedlinePlus, fetched 2026-10-30, sha256 e0fbefd889f779a2537ed84f7649157343e52043a577e2a21ddaf9c416844161). It names the A.D.A.M. encyclopedia, drug monographs and many images as copyrighted; this atlas uses only the page summary text. The raw page is committed in the atlas repository. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only.
-
Supports Transthyretin amyloidosis (MedlinePlus Genetics)
- Locator
- Description, para 4, sentence 1
- How it applies
- The cardiac form of transthyretin amyloidosis.
- Retrieved
- Source effective date
- 2023-11-08
- Source state
- Current
- Version fingerprint
2defdb0688632ca71f852b099c8cf88007a300011d1f7ac09aee892ddf87379c- Reuse basis
- MedlinePlus states that works produced by the federal government are not copyrighted, and lists the summaries on health topic pages and Genetics pages as public domain (the page titled Linking to and Using Content from MedlinePlus, fetched 2026-10-30, sha256 e0fbefd889f779a2537ed84f7649157343e52043a577e2a21ddaf9c416844161). It names the A.D.A.M. encyclopedia, drug monographs and many images as copyrighted; this atlas uses only the page summary text. The raw page is committed in the atlas repository. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only.
-
Supports Transthyretin amyloidosis (MedlinePlus Genetics)
- Locator
- Description, para 4, sentence 2 (first part)
- How it applies
- First two findings of the list.
- Retrieved
- Source effective date
- 2023-11-08
- Source state
- Current
- Version fingerprint
2defdb0688632ca71f852b099c8cf88007a300011d1f7ac09aee892ddf87379c- Reuse basis
- MedlinePlus states that works produced by the federal government are not copyrighted, and lists the summaries on health topic pages and Genetics pages as public domain (the page titled Linking to and Using Content from MedlinePlus, fetched 2026-10-30, sha256 e0fbefd889f779a2537ed84f7649157343e52043a577e2a21ddaf9c416844161). It names the A.D.A.M. encyclopedia, drug monographs and many images as copyrighted; this atlas uses only the page summary text. The raw page is committed in the atlas repository. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact Evaluated for this: Acoramidis
Applies to Recipient not specified Adults with the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis, as described in the US label of Attruby
Population, setting and follow-up
- Adults with the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM), as the indications section of the label describes them. The passages read give no other age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of Attruby (acoramidis hydrochloride tablets; BridgeBio Pharma, Inc., application NDA216540; the version dated 2026-06-29 in openFDA) calls the product a transthyretin stabilizer. It lists the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults, to reduce cardiovascular death and cardiovascular-related hospitalization, as the indication.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and the atlas holds no trial result for it. The label has no boxed warning in the record read. Contraindications, other warnings, interactions, the pregnancy, lactation and pediatric sections and dosing were not recorded. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Tafamidis
Applies to Adult Adults with transthyretin amyloid cardiomyopathy (wild-type or hereditary), as described in the US label of Vyndaqel and Vyndamax
Population, setting and follow-up
- Adults with cardiomyopathy caused by wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), as the label states its indication.
- Prescription medicine taken by mouth; the label record states no care setting
- United States (labeling approved by the US Food and Drug Administration)
- Adults
The openFDA records list two tafamidis applications, both with an original submission approved on 3 May 2019: NDA212161 for Vyndamax (tafamidis; class Type 2 - New Active Ingredient; applicant FOLDRX PHARMS), listed as a prescription product, and NDA211996 for Vyndaqel (tafamidis meglumine; class Type 1 - New Molecular Entity), listed as discontinued. One label record (version 15, effective 12 May 2026) still names both brands and says they are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults, to reduce cardiovascular mortality and cardiovascular-related hospitalization.Limitations. An FDA approval is a decision about a medicine, not a finding about how much it helps any person. The discontinued status of Vyndaqel is the marketing status in the openFDA application record, and the label record still lists the brand, so the two sources are given side by side without reconciling them. The two applications are for different forms of the substance (the meglumine salt and tafamidis itself). The label record is a copy and may not show later changes. openFDA says not to rely on its data for decisions about medical care. The atlas gives no dose.
-
Claim, not a settled fact Evaluated for this: Vutrisiran
Applies to Recipient not specified Adults with the polyneuropathy of hereditary transthyretin-mediated amyloidosis, or with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, as described in the US label of Amvuttra
Population, setting and follow-up
- Adults in the two groups the indications section of the label names: adults with the polyneuropathy of hereditary transthyretin-mediated amyloidosis, and adults with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis. The passages read give no other age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of Amvuttra (vutrisiran injection; Alnylam Pharmaceuticals, Inc., application NDA215515; the version dated 2025-11-06 in openFDA) calls the product a transthyretin-directed small interfering RNA. It lists two indications in adults: the polyneuropathy of hereditary transthyretin-mediated amyloidosis, and the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and the atlas holds no trial result for it. The polyneuropathy indication concerns the nerves, not the heart, and the atlas gives it no page of its own. The label read has no boxed warning section. Contraindications, other warnings, interactions, the pregnancy, lactation and pediatric sections and dosing were not recorded. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry trials 19
Record details
- Record id
cardio:cardiac-amyloidosis- Content hash
1ec06350245a489adcab76a2036284dfa48f8db9bf2086d8307278dc2906521f